Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 7/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299358 | 0.99 | GPR4 (0.43) | GPR4CTSKLTA4HKMT2APLA2G1B | |
| SCHEMBL30299374 | 0.92 | SMN1; SMN2 (0.35) | GPR4CTSKLTA4HKMT2AKDM4E | |
| SCHEMBL30299399 | 0.91 | GPR4 (0.37) | GPR4CTSKKMT2AOPRM1OPRK1 | |
| SCHEMBL30299376 | 0.89 | GPR4 (0.38) | GPR4CTSKLTA4H | |
| SCHEMBL30299400 | 0.89 | LTA4H (0.47) | LTA4HOPRM1OPRK1HRH3KDM4E | |
| SCHEMBL30299272 | 0.88 | LTA4H (0.46) | LTA4HOPRM1OPRK1HRH3KDM4E | |
| SCHEMBL30299294 | 0.84 | L3MBTL3 (0.47) | KMT2AHRH3KDM4EALDH1A1TSHR | |
| SCHEMBL30299395 | 0.81 | TSHR (0.38) | LTA4HKMT2AOPRM1OPRK1KDM4E | |
| SCHEMBL30299386 | 0.81 | SIGMAR1 (0.40) | LTA4HKMT2AOPRM1OPRK1HRH3 | |
| SCHEMBL4987905 | 0.81 | GPR4 (0.33) | GPR4CTSKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |